

Unintended Consequences of Healthcare & Life Science Legislation

A Global Symposium for Healthcare & Life Science Experts

2nd Annual

Wednesday, October 15, 2014
8:00AM - 3:45PM EST
975 F Street, N.W.
Washington, D.C. 20004



Presented By





ORGANIZATIONS REPRESENTED

American Association of University Women

Americas Health Foundation

Amgen

ATCC

Avalere Health

Avanir Pharmaceuticals

Center for Healthcare Innovation

Chevy Chase BioPartners

Children's Hospital Los Angeles

Crowell & Moring

Curant Health

DC Department of Health

DC Greens

Forty Million Beats

Genentech

Government of the District of Columbia

Healthcare Council of the National Capital Area

Innovation Strategies

Inside Washington Publishers

Ipsos

Johns Hopkins University

Leed Management Consulting

Marywood University

MedImmune

Merck

MicroAire Surgical Instruments

National Heart, Lung, and Blood Institute (NIH)

National Institutes of Health

Neuralstem

Physicians Committee for Responsible Medicine

Quest Diagnostics

ROI Squared

Seeking Alpha

Sequella

Seyfarth Shaw

Shire

Society of Physician Entrepreneurs

U.S. Pharmacopeia

United Health Group

University of Maryland School of Medicine

Women In Bio

Women In Healthcare & Life Sciences

Unintended Consequences of Healthcare & Life Science Legislation Symposium

PRESENTED BY

Center for Healthcare Innovation

CHI is a 501(c)(3), non-profit research center committed to excellence and innovation in the global life sciences industries, primarily the biotech, medical device, and pharmaceutical sectors. We aim to be the world's #1 source of rigorous, objective thought-leadership and innovative solutions for the international life science ecosystem.



Women In Healthcare & Life Sciences

WIHLS is an initiative to mentor and facilitate the professional development and advancement of women in healthcare and the life sciences worldwide. Through dedicated mentor-mentee relationships among women of all ages, we empower women to advance their careers, maximize their full potential, and realize their ability to affect change.



Women In Healthcare
& Life Sciences

Planning Committee



Mr. Joseph Gaspero
President & Co-Founder
Center for Healthcare Innovation



Dr. James Gillespie
Chief Executive Officer & Co-Founder
Center for Healthcare Innovation



Ms. Ravi Gupta
Advisor, Center for Healthcare Innovation
Innovation, IP, PE/VC, and PSD Strategist,
The World Bank



Mr. Joff Masukawa
Special Advisor, Center for Healthcare Innovation
Vice President and Global Head, Government
Relations and Public Affairs, Shire

2014

Supporters

HOST

SEYFARTH
ATTORNEYS SHAW LLP

Breadth. Depth. **Results.**

SPONSORS

Shire

MEDIA

INSIDE WASHINGTON
PUBLISHERS

exclusive, relevant news about the federal
policy-making process

PROMOTION PARTNERS

JOHNS HOPKINS
UNIVERSITY

Center for 
Biotechnology Education

HC
NCA
Healthcare Council of the
National Capital Area

Unintended Consequences of Healthcare & Life Science Legislation Symposium



What are the **unforeseen outcomes** of a rapidly-changing **healthcare landscape**?

Unintended consequences are the unanticipated and unforeseen outcomes from government action that are not the outcomes intended by the executive and legislative branches. There are three basic categories: (i) a positive, unexpected benefit, (ii) a negative, unexpected detriment, and (iii) a perverse effect substantially contrary to the original purpose of the law or regulation. Examples in healthcare and life sciences include the *Orphan Drug Act of 1983* and the emergence of mini-med healthcare plans (total coverage capped at very low amounts). There are likely to be a wide array of unintended consequences resulting from the new *Patient Protection and Affordable Care Act* in the U.S., as well as various healthcare legislation around the world. The Unintended Consequences of Healthcare & Life Science Legislation Symposium is a non-partisan forum for healthcare and life science leaders from around the globe to discuss these unintended consequences of healthcare legislation in the U.S. around the world.

Dear Symposium Attendees,

On behalf of the Center for Healthcare Innovation (CHI), we welcome you to the 2nd annual *Unintended Consequences of Healthcare & Life Science Legislation Symposium*. It is a privilege to welcome back those who participated in last year's symposium, as well as to greet newcomers to our collaborative discussion.

Our goal for today is to provide an intimate, non-partisan, and collaborative setting for leading life science and healthcare executives, NGOs, government personnel, thought-leaders, scientists, entrepreneurs, investors, students, professors, and innovators to discuss healthcare legislation and a rapidly-changing healthcare environment. The event will feature panel discussions and distinguished speakers comprised of leading healthcare and life science experts and key opinion leaders. We hope today's symposium provides a collaborative setting to discuss the challenges and opportunities surrounding the unintended consequences of healthcare and life sciences legislation.

We would like to thank all of today's supporters, sponsors, host, co-promotion partners, and distinguished moderators and panelists. Finally, we would like to thank you all for joining today's discussion. We wish you an informative and productive afternoon, and hope you enjoy today's discussion surrounding healthcare and life sciences legislation.

Kindest Regards,
Symposium Planning Committee
Center for Healthcare Innovation

Unintended Consequences of Healthcare & Life Science Legislation Symposium

Agenda

8:00 - 9:00	Registration & Networking
9:00 - 9:15	Opening Remarks
9:15 - 9:45	Distinguished Welcoming Address
10:00 - 11:00	<i>Industry Perspectives</i> Panel
11:30 - 12:30	<i>Governmental/NGO Perspectives</i> Panel
12:30 - 1:15	Lunch
1:15 - 2:00	Distinguished Keynote Address
2:30 - 3:30	<i>Is Innovation at Risk?</i> Panel Discussion
3:30 - 3:45	Concluding Remarks

Distinguished Welcoming Address: Elizabeth Flury, Chief Strategy Officer of the Children's National Health System, will set the tone for the symposium. Her position requires her to be proactive regarding healthcare reform. Ms. Flury will describe how organizations can calmly face the shifting tides of change brought about by healthcare and life science legislation.

***Industry Perspectives* Panel:** The *Affordable Care Act* and other healthcare and life sciences legislation will likely have both positive and negative unintended consequences for these industries. This panel, comprised of some of the country's leading healthcare and life science executives and thought-leaders, will analyze and discuss industry reactions to healthcare and life science legislation.

***Governmental/NGO Perspectives* Panel:** We often contemplate how the industry must react to legislation, but we do not always consider why these reforms are constructed and the guidelines that must be followed when responding to the uncertainty of the healthcare landscape. This panel, comprised of leading professionals and thought-leaders in the government and NGO sectors, will consider regulation and reform obstacles and successes.

Distinguished Keynote Address: As Director of the District of Columbia Department of Health, Dr. Joxel Garcia has firsthand experience untangling the unforeseen consequences that policy and regulation have on the healthcare and life sciences. Dr. Garcia's broad experience and previous roles as Assistant Secretary for Health (ASH) within the U.S. Department of Health and Human Services, Four-star Admiral in the U.S. Public Health Service, U.S. Representative to the Executive Board of the World Health Organization, Founding Partner in Faunus Global and Aegis Health Security, and President of the Ponce School of Medicine & Health Sciences, give him a robust understanding of the opportunities and challenges of healthcare and life science legislation.

***Is Innovation at Risk?* Panel:** Recent healthcare and life science legislation, including the *Affordable Care Act*, focuses on reducing healthcare costs and expanding coverage to all. However, legislation often has the unintended consequences of stifling innovation. This panel explores the broader intersection of healthcare and life science legislation with innovation in these industries and offers potential solutions and best practices for encouraging innovation.



AGENDA

Registration & Networking 8:00-9:00

Opening Remarks 9:00-9:15

- **Mr. Joff Masukawa**, Vice President and Global Head, Government Relations and Public Affairs, Shire

Distinguished Welcoming Address 9:15-9:45

- **Ms. Elizabeth Flury**, Executive Vice President and Chief Strategy Officer, Children's National Health System

Industry Perspectives Panel Discussion 10:00-11:00

- **Ms. Dolly Judge**, Vice President, Government Relations, Quest Diagnostics (Moderator)
- **Dr. Lisa Egbunu-Davis**, Co-Founder & Director, ROI Squared
- **Dr. Thomas Felix**, Director, R&D Policy, Global Regulatory Affairs and Safety, Amgen
- **Dr. Carol Nancy**, Chief Executive Officer, Sequella
- **Dr. Andrew Robertson**, Director, Global Regulatory Policy, Merck; Visiting Scholar, Center for Emerging and Neglected Diseases, UC Berkeley
- **Ms. Nicole Tapay**, Director, Global Public Policy, Eli Lilly and Company
- **Ms. Sheryl Tatar Dacso**, Partner, Seyfarth Shaw
- **Dr. Gillian Woollett**, Senior Vice President, Avalere Health

Networking Break 11:00-11:30

Governmental/NGO Perspectives Panel Discussion 11:30-12:30

- **Ms. Lauren Shweder Biel**, Executive Director, DC Greens (Moderator)
- **Ms. Erica Ahmed**, Senior Health Communication Specialist, Leed Management Consulting, Director of Public Education, Mental Health America (former)
- **Dr. Stephen Groft**, Director, Office of Rare Diseases Research, National Institutes of Health
- **Dr. Lynn Johnson Langer**, Director, Enterprise & Regulatory Science Programs, Center for Biotechnology Education, Johns Hopkins University
- **Mr. Peter Pappas**, Principal, Innovation Strategies; Chief of Staff, United States Patent and Trademark Office, U.S. Department of Commerce (former)
- **Dr. Gautam Prakash**, Intellectual Property Advisor, National Heart, Lung, and Blood Institute (NIH); Patent Examiner, United States Patent and Trademark Office
- **Mr. Dick Salvatierra**, President, Americas Health Foundation



AGENDA

Lunch 12:30-1:15

Distinguished Keynote Address 1:15-2:00

- **Dr. Joxel Garcia**, Director, District of Columbia Department of Health

Networking Break 2:00-2:30

Is Innovation at Risk Panel Discussion 2:30-3:30

- **Dr. Jeffrey Hausfeld**, Founder & Chairman, Society of Physician Entrepreneurs (Moderator)
- **Ms. Debra Bowes**, President Emeritus/National Board Member, Women In Bio; Founder & President, Chevy Chase BioPartners
- **Dr. Edward Buckley**, Senior Director, US Government Relations and Public Policy, Shire
- **Dr. Elizabeth Cobbs**, Executive Director, HTA Strategy, Merck
- **Dr. Jayne Morgan**, Chief Medical Officer, The American Chemistry Council (former); Owner and Principal Consultant, Forty Million Beats
- **Mr. Siva Narayanan**, Senior Vice President, Ipsos
- **Ms. Teresa Stanek Rea**, Partner, Crowell & Moring; Deputy Undersecretary of Commerce for Intellectual Property and Deputy Director; U.S. Patent and Trademark Office (former)
- **Ms. Crystal Vanuch**, Head of Government Affairs and Policy, Avanir Pharmaceuticals

Closing Remarks 3:30-3:45

- **Mr. Joff Masukawa**, Vice President and Global Head, Government Relations and Public Affairs, Shire

Distinguished Welcoming Address

HOST

SEYFARTH
ATTORNEYS SHAW^{LLP}

Breadth. Depth. **Results.**

SPONSORS

Shire

Distinguished Welcoming Address



Ms. Elizabeth Flury

Ms. Elizabeth Flury, Executive Vice President and Chief Strategy Officer
Children's National Health System

Elizabeth Flury, MA, is Executive Vice President and Chief Strategy Officer of Children's National Health System. She joined Children's National in 2012 as the organization's first Chief Strategy Officer. She leads the formulation and execution of new, innovative strategy at Children's National designed to ensure the organization's preparedness for healthcare reform.

Ms. Flury came to Children's National from the Johns Hopkins Health System, where she served as the Senior Director, Health Care Transformation and Strategic Planning, where she played a significant leadership role in the organization's preparations for healthcare reform. Before joining Johns Hopkins, Ms. Flury came from KPMG, where she provided national leadership to KPMG's Health Care Strategy and Governance Practice. Ms Flury has also owned and operated her own consulting firm.

Ms. Flury earned her B.S. in Business Administration from Elizabethtown College in PA, and her M.A. in Organizational Psychology from Immaculata University, also in PA.

Distinguished Keynote Address

Distinguished Keynote Address



Dr. Joxel Garcia

Director
District of Columbia
Department of Health

Dr. Joxel Garcia, MD, MBA, currently serves as the Director for the District of Columbia Department of Health (DOH). Under his leadership, the department has embarked on several innovative public health initiatives to improve and protect the health of residents, visitors, and those doing business in the District of Columbia. His health priorities include ensuring the District of Columbia receives national public health accreditation. He has also spearheaded the development of an infant mortality reduction program in collaboration with several private and public sector community partners and funders. Dr. Garcia also leads the charge in reducing/eliminating cervical cancer and other health disparities. His priorities also include creating International Health Centers of Excellence, to establish the District of Columbia as the premiere destination for research, training, and medical tourism by the year 2015.

Dr. Garcia is committed to public health efforts to serve District of Columbia residents. His passion for health equality and identifying the social determinants of health in order to mitigate disparities is evident in the department's policy, programs, and initiatives. Prior to his appointment to the Department of Health, Dr. Garcia served as the 13th Assistant Secretary for Health (ASH) within the U.S. Department of Health and Human Services. As the Assistant Secretary for Health, he was the primary advisor to the Secretary of Health on matters involving the nation's public health system and health science. He also oversaw the U.S. Public Health Service and its Commissioned Corps and served with the rank of Admiral. In this position, Dr. Garcia was the highest ranking public health officer in the U.S. He also served as the U.S. Representative to the Executive Board of the World Health Organization.

Dr. Garcia's experience in public health encompasses health care systems, bioterrorism, public health preparedness and disaster mitigation, health policy, and global health affairs. Dr. Garcia served as the Commissioner of Public Health for the state of Connecticut and served as Deputy Director of the Pan American Health Organization (PAHO)/Regional Office Western Hemisphere for the World Health Organization. Most recently, he served as the President of the Ponce School of Medicine & Health Sciences, Ponce, and Puerto Rico.

A native of Puerto Rico, Dr. Garcia currently resides in Washington, D.C.

MEDIA



PROMOTION PARTNERS



Center for 
Biotechnology Education





Supporters



Increasing access to research

Improving patient care

CLINICAL RESEARCH EXCHANGE



MCHC

Metropolitan Chicago
Healthcare Council



Center for
Healthcare
Innovation

FOR MORE INFORMATION CONTACT:

Karen E. Barnes, RN, MSN, Director, Clinical Research Exchange (312) 906-6135 or kbarnes@mchc.com

Joel Villegas, Project Coordinator, Clinical Research Exchange (312) 906-6154 or jvillega@mchc.com

About the Clinical Research Exchange (CRE)

CRE is a collaboration between the Metropolitan Chicago Healthcare Council (MCHC) and the Center for Healthcare Innovation (CHI). CRE is a clinical research alliance that streamlines the research process, enabling sites to enroll more patients more quickly.

CRE has formed a unique network of provider institutions, principal investigators (PIs), trial sponsors, and contract research organizations to increase the quality and quantity of clinical trials throughout the metropolitan Chicago area. Through a menu of services, CRE provides the flexibility to meet your research needs. CRE services and turnkey solutions include:

- Identification of qualified sites, investigators, and patients
- Quicker trial start-up
- Comprehensive CRE membership network
- Advanced education for PIs and research staff

Supporters

SEYFARTH
SHAW

Committed to Excellence



Seyfarth Shaw LLP is passionate about the quality of our work. We are grateful to see that others have noticed that passion, too.



Innovative Law Firm of the Year
Received the top two awards for excellence in innovation and technology used by law firms presented by the International Legal Technology Association (ILTA).



Client Service Elite Honors
For the third consecutive year, Seyfarth was named to BTI Consulting's Client Service 30 list, which represents the "cream of the crop" of law firms on client service.

Financial Times
US Innovative Lawyers Report

Financial Times US Law Firm Innovator
Seyfarth earned a spot among the *FT US Innovative Lawyers 2013* index of the most innovative firms, including top-ranking honors in the Business of Law.



ACC Value Champion
Recognized as an ACC Value Champion for our innovative collaboration with a client to manage its outsourcing of contracts.



Innovation Leader
Recognized as the top-ranking firm to use innovation to deliver legal service aligned with client needs based on corporate counsel feedback from the world's largest companies.



Most Innovative
Awarded to Managing Partner Stephen Poor for his instrumental role in the creation and evolution of the firm's client service model, *SeyfarthLean*.



InnovAction Awards
Recognized for "outstanding innovation in the delivery of legal services" by the College of Law Practice Management (COLPM).

www.seyfarth.com

©2014 Seyfarth Shaw LLP #14-1925

Shire



We enable people with life-altering conditions to lead better lives.

Shire
To be as brave as the people we help.

SoPE

society of physician entrepreneurs

The Society of Physician Entrepreneurs is a global biomedical and healthcare innovation network. Founded by three physicians in early 2011, SoPE is an international nonprofit biomedical and health innovation network helping members get their ideas to patients. Membership is open to both medical professionals and other stakeholders in healthcare. SoPE is working to put healthcare innovations on the fast track---The vision, mission, and activities of the Society are ultimately about the benefit to the general public of healthcare improvements; better treatment, greater and faster access, and lower costs. To learn more about SoPE please visit our website at www.sopenet.org

Annual Conferences

Leader of 5 collaborative events

- Diversity, Inclusion, & Life Sciences Symposium (Chicago)
- Emerging Markets in Life Sciences I Symposium: The Power of Partnerships (New York)
- Innovative Partnerships in Healthcare Roundtable (New York)
- Emerging Markets in Life Sciences II Symposium: The Role of Relationships (San Francisco)
- Unintended Consequences of Healthcare & Life Sciences Legislation Symposium (Washington, D.C.)

Who We Are

An organization comprised of accomplished and talented individuals from a rich array of backgrounds, cultures, and experiences:

GLOBAL COUNCIL

- **Dr. Bavaguthu Raghuram Shetty**, Founder, Managing Director & CEO, NMC Group
- **Dr. Bandi Parthasaradhi Reddy**, Founder, Chairman, CEO, & Managing Director, Hetero Group
- **Dr. Anita Goel**, Founder, Chairman, & Scientific Director, Nanobiosym; Chairman & CEO, Nanobiosym Diagnostics

BOARD OF DIRECTORS

- **Mr. Michel J. Feldman** (Chairman), Partner, Seyfarth Shaw; Founding Board Member, Watson Pharmaceuticals
- **Dr. Nelson L. Levy** (Vice Chairman), Chairman & CEO, CoreTechs Corporation
- **Dr. Samir Bhattacharyya**, World Wide Director of Market Access, Depuy Mitek, a Johnson & Johnson Company
- **Dr. James J. Gillespie**, Chief Executive Officer & Co-Founder, Center for Healthcare Innovation
- **Mr. Sanjay Kadaveru**, Co-Founder, Center for Healthcare Innovation
- **Dr. Linda McAllister**, Chief Medical Officer & Vice President of R&D, PharmaJet
- **Dr. Andrea Small-Howard**, Chief Science Officer, GB Sciences

EXECUTIVE COUNCIL

- **Mr. Dennis Urbaniak** (Chairman), Managing Director, Accenture
- **Dr. Laurent Audoly** (Vice Chairman), Senior Vice President, Research & Development, Fabre Laboratories
- **Ms. Joanna Brougher**, Senior Council, Vaccinex
- **Mr. Lewis Feldberg**, Chief Executive Officer, Esteve USA (former)
- **Dr. Albert Jaramillo**, Vice President, Human Resources, Global R&D, Pfizer (retired)
- **Mr. Michael Naimoli**, Vice President Life Sciences, Solution Management, SAP Labs (former)
- **Ms. Julie Sawyer-Montgomery**, Vice President, Global Medication Management Systems & Business Insights, Hospira
- **Mr. Richard Smith**, Managing Director, Life Sciences & Specialty Services, FedEx Express
- **Dr. Eckhard von Keutz**, Senior Vice President, Head Global Early Development, Bayer HealthCare

STRATEGY GROUP

- **Mr. James Jordan** (Chairman), Distinguished Service Professor in Healthcare & Biotechnology Management, Carnegie Mellon University
- **Mr. Mark Kwatia** (Vice Chairman), Diagnostics Assay Design, Abbott Laboratories
- **Dr. G. Randall Green**, Founder, Secant Therapeutics
- **Dr. Marco Quarta**, Director, Institute for Bioengineering in Stem Cell & Regenerative Medicine, Stanford University
- **Dr. Kate Rosenbluth**, Biodesign Innovation Fellow, Stanford University
- **Dr. James Su**, Senior Research Engineer, Abbott Vascular

SPECIAL ADVISORS

- **Mr. Mark Hattas**, Founder, Former CEO, & Chairman, Geneca
- **Mr. Joff Masukawa**, Vice President and Global Head, Government Relations and Public Affairs
- **Dr. Stuart Rich**, Professor of Medicine, University of Chicago